Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barone, P.
Right arrow Articles by Chase, T. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barone, P.
Right arrow Articles by Chase, T. N.
NEUROLOGY 1987;37:1592
© 1987 American Academy of Neurology

Dopaminergic mechanisms in hemiparkinsonian monkeys

P. Barone, MD, K. S. Bankiewicz, MD, G. U. Corsini, MD, I. J. Kopin, MD and T. N. Chase, MD

From the Experimental Therapeutics Branch and Intramural Research Program, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, MD.

The motor effects of direct agonists which act selectively on certain dopamine receptors were studied in monkeys rendered hemiparkinsonian by unilateral intracarotid injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). The D-2 dopamine agonist, LY171555, but not the D-1 agonist, SKF 38393, reduced parkinsonian signs and induced rotation away from, the side of the nigral lesion. When administered together, SKF 38393 diminished the LY 171555-induced turning in a dose-dependent manner. A selective D-1 antagonist, SCH 23390, induced mild and brief rotation when administered alone. These results suggest that D-2 receptor stimulation is necessary to ameliorate parkinsonism, but that pharmacologic manipulation of both D-1 and D-2 receptors may be required for an optimal therapeutic response.

Address correspondence and reprint requests to Dr. Chase, Experimental Therapeutics Branch, NINCDS, Building 10, Room 5C103, Bethesda, MD 20892.

Presented in part at the thirty-eighth annual meeting of the American Academy of Neurology, New Orleans, LA, April 1986.

Received September 22, 1986. Accepted for publication in final form January 14, 1987.




This article has been cited by other articles:


Home page
 J. Neurophysiol.Home page
M. A. Kliem, N. T. Maidment, L. C. Ackerson, S. Chen, Y. Smith, and T. Wichmann
Activation of Nigral and Pallidal Dopamine D1-Like Receptors Modulates Basal Ganglia Outflow in Monkeys
J Neurophysiol, September 1, 2007; 98(3): 1489 - 1500.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. E. Asin, E. F. Domino, A. Nikkel, and K. Shiosaki
The Selective Dopamine D1 Receptor Agonist A-86929 Maintains Efficacy with Repeated Treatment in Rodent and Primate Models of Parkinson's Disease
J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 454 - 459.
[Abstract] [Full Text]

Home page
 J PsychopharmacolHome page
J. L. Waddington
Functional interactions between D-1 and D-2 dopamine receptor systems: their role in the regulation of psychomotor behaviour, putative mechanisms, and clinical relevance
J Psychopharmacol, January 1, 1989; 3(2): 54 - 63.
[PDF]